The Cantor Fitzgerald Analysts Give Radius Health Inc (RDUS) a $65.00 Price Target

The Cantor Fitzgerald Analysts Give Radius Health Inc (RDUS) a $65.00 Price Target

Several other equities analysts also recently issued reports on the stock. HC Wainwright restated a buy rating and issued a $66.00 price objective (down previously from $71.00) on shares of Radius Health in a research note on Friday, March 24th. Zacks Investment Research upgraded shares of Radius Health from a sell rating to a hold rating in a research note on Thursday, May 4th. Canaccord Genuity restated a buy rating on shares of Radius Health in a research note on Friday, April 28th. Maxim Group restated a sell rating on shares of Radius Health in a research note on Monday, May 1st. Finally, Jefferies Group LLC decreased their price objective on shares of Radius Health from $40.00 to $34.00 and set a hold rating for the company in a research note on Tuesday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Radius Health has a consensus rating of Hold and a consensus price target of $56.83.

Cantor Fitzgerald set a $65.00 target price on Radius Health Inc (NASDAQ:RDUS) in a research report released on Sunday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Radius Health (RDUS) traded down 0.03% during mid-day trading on Friday, hitting $35.08. The stock had a trading volume of 731,634 shares. Radius Health has a 52-week low of $31.58 and a 52-week high of $59.88. The stock’s market cap is $1.52 billion. The firm has a 50-day moving average of $36.31 and a 200-day moving average of $41.35.

In related news, major shareholder Growth N. V. Biotech bought 40,000 shares of the company’s stock in a transaction on Tuesday, May 30th. The stock was bought at an average cost of $34.21 per share, with a total value of $1,368,400.00. Following the completion of the acquisition, the insider now owns 5,038,799 shares in the company, valued at approximately $172,377,313.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Growth N. V. Biotech bought 35,000 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was bought at an average cost of $33.44 per share, with a total value of $1,170,400.00. Following the completion of the acquisition, the insider now owns 4,890,799 shares of the company’s stock, valued at approximately $163,548,318.56. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 678,400 shares of company stock valued at $24,321,465. 16.80% of the stock is currently owned by corporate insiders. A number of hedge funds and other institutional investors have recently modified their holdings of RDUS. C WorldWide Group Holding A S boosted its position in shares of Radius Health by 0.6% in the first quarter. C WorldWide Group Holding A S now owns 7,397 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 43 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 46 shares during the period. Principal Financial Group Inc. boosted its position in shares of Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 180 shares during the period. OppenheimerFunds Inc. boosted its position in shares of Radius Health by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock worth $11,658,000 after buying an additional 831 shares during the period. Finally, Swiss National Bank boosted its position in shares of Radius Health by 2.1% in the first quarter. Swiss National Bank now owns 49,700 shares of the biopharmaceutical company’s stock worth $1,921,000 after buying an additional 1,000 shares during the period. 95.84% of the stock is owned by institutional investors.

Radius Health Company Profile Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:RDUS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Radius Health Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Radius Health Inc and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment